2. Search Result
Search Result
Results for "

(2S,6S)-2,6-Diaminoheptanedioic acid-<sup>13</sup>C<sub>7</sub>,<sup>15</sup>N<sub>2</sub>

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

3

Peptides

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P4146
    Survodutide

    BI 456906

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide
  • HY-W334800S
    (2S,6S)-2,6-Diaminoheptanedioic acid-13C7,15N2

    L-threo-2,6-Diaminopimelic acid-<sup>13sup>C<sub>7sub>,<sup>15sup>N<sub>2sub>

    		 Isotope-Labeled Compounds Others
    (2S,6S)-2,6-Diaminoheptanedioic acid- 13C7, 15N2 (L-threo-2,6-Diaminopimelic acid- 13C7, 15N2) is 13C and 15N-labeled (2S,6S)-2,6-diaminoheptanedioic acid (HY-W334800).
    (2S,6S)-2,6-Diaminoheptanedioic acid-13C7,15N2
  • HY-W334800S2
    (2S,6S)-2,6-Diaminoheptanedioic acid-13C7

    L-threo-2,6-Diaminopimelic acid-<sup>13sup>C<sub>7sub>

    		 Isotope-Labeled Compounds Others
    (2S,6S)-2,6-Diaminoheptanedioic acid- 13C7 (L-threo-2,6-Diaminopimelic acid- 13C7) is 13C-labeled (2S,6S)-2,6-diaminoheptanedioic acid (HY-W334800).
    (2S,6S)-2,6-Diaminoheptanedioic acid-13C7
  • HY-W334800S1
    (2S,6S)-2,6-Diaminoheptanedioic acid-15N2

    L-threo-2,6-Diaminopimelic acid-<sup>15sup>N<sub>2sub>

    		 Isotope-Labeled Compounds Others
    (2S,6S)-2,6-Diaminoheptanedioic acid- 15N2 (L-threo-2,6-Diaminopimelic acid- 15N2) is 15N labeled (2S,6S)-2,6-diaminoheptanedioic acid (HY-W334800).
    (2S,6S)-2,6-Diaminoheptanedioic acid-15N2
  • HY-P10341
    ZP3022

    		GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin, which has the ability to continuously improve glycemic control. Meanwhile, ZP3022 can effectively increase the mass of β-cells, promote β-cell proliferation, and enhance the average islet mass. ZP3022 can be used in research for anti-diabetic treatments .
    ZP3022
  • HY-P4146A
    Survodutide TFA

    BI 456906 TFA

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: